The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) hit a new 52-week high and has $38.31 target or 23.00% above today’s $31.15 share price. The 8 months bullish chart indicates low risk for the $1.10B company. The 1-year high was reported on Nov, 14 by Barchart.com. If the $38.31 price target is reached, the company will be worth $253.00 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 83,030 shares traded hands. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 24.59% since April 12, 2016 and is uptrending. It has outperformed by 19.61% the S&P500.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage
Out of 6 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. $89 is the highest target while $32 is the lowest. The $41.67 average target is 33.77% above today’s ($31.15) stock price. AMAG Pharmaceuticals has been the topic of 16 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, May 4 report. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Buy” rating by Jefferies on Thursday, August 11. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Thursday, November 19 by Deutsche Bank. The firm has “Buy” rating by Needham given on Thursday, October 27. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Outperform” rating by Raymond James on Tuesday, September 1. Deutsche Bank reinitiated the stock with “Hold” rating in Thursday, September 3 report. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Deutsche Bank on Wednesday, November 4. Jefferies initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Tuesday, August 18 with “Buy” rating. The stock has “Strong-Buy” rating given by Zacks on Wednesday, August 19. The rating was downgraded by Raymond James on Wednesday, May 4 to “Market Perform”.
According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.CombidexÂ®, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.”
Insitutional Activity: The institutional sentiment decreased to 0.83 in 2016 Q2. Its down 0.79, from 1.62 in 2016Q1. The ratio fall, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Moreover, Camber Cap Mngmt Ltd Limited Liability Company has 0.69% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 600,000 shares. Principal Fincl Group last reported 276,923 shares in the company. Greywolf Capital Management Lp has invested 3.44% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Northern Tru accumulated 411,854 shares or 0% of the stock. Prudential Inc last reported 0.02% of its portfolio in the stock. Blackrock Institutional Tru Na reported 903,089 shares or 0% of all its holdings. The Colorado-based Janus Cap Limited Liability Com has invested 0.07% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Sector Pension Board has 24,700 shares for 0.01% of their US portfolio. Royal Bank & Trust Of Canada last reported 620,453 shares in the company. Spot Trading Limited Liability Com accumulated 0.01% or 13,012 shares. New York State Teachers Retirement Sys holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 20,325 shares. Healthinvest Ptnrs has 671,585 shares for 7.37% of their US portfolio. Ubs Asset Mgmt Americas holds 0% or 16,656 shares in its portfolio. Moreover, Alliancebernstein L P has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 64,173 shares. Huntington State Bank has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Insider Transactions: Since October 20, 2016, the stock had 0 buys, and 1 insider sale for $122,462 net activity. On Thursday, October 20 Krop Julie sold $122,462 worth of the stock or 4,938 shares.
AMAG Company Profile
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.